FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of macular edema…
Read More...
Read More...